Abbott Laboratories (NYSE:ABT) Shares Acquired by SeaCrest Wealth Management LLC

SeaCrest Wealth Management LLC lifted its stake in shares of Abbott Laboratories (NYSE:ABT) by 3.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 19,886 shares of the healthcare product maker’s stock after purchasing an additional 634 shares during the quarter. SeaCrest Wealth Management LLC’s holdings in Abbott Laboratories were worth $1,664,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of ABT. Vanguard Group Inc. grew its stake in Abbott Laboratories by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 148,332,948 shares of the healthcare product maker’s stock valued at $12,474,801,000 after acquiring an additional 2,262,152 shares during the last quarter. BlackRock Inc. grew its stake in Abbott Laboratories by 1.8% in the 2nd quarter. BlackRock Inc. now owns 126,525,967 shares of the healthcare product maker’s stock valued at $10,640,833,000 after acquiring an additional 2,199,601 shares during the last quarter. Janus Henderson Group PLC grew its stake in Abbott Laboratories by 0.9% in the 2nd quarter. Janus Henderson Group PLC now owns 17,025,499 shares of the healthcare product maker’s stock valued at $1,431,723,000 after acquiring an additional 149,307 shares during the last quarter. Nuveen Asset Management LLC grew its stake in Abbott Laboratories by 7,888.6% in the 2nd quarter. Nuveen Asset Management LLC now owns 12,377,944 shares of the healthcare product maker’s stock valued at $1,040,985,000 after acquiring an additional 12,222,999 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Abbott Laboratories by 2.7% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 7,653,964 shares of the healthcare product maker’s stock valued at $643,699,000 after acquiring an additional 199,283 shares during the last quarter. 73.76% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts recently commented on ABT shares. Zacks Investment Research cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating and set a $93.00 price objective on the stock. in a research note on Wednesday, August 21st. Jefferies Financial Group increased their price objective on shares of Abbott Laboratories from $80.00 to $98.00 and gave the company a “buy” rating in a research note on Thursday, July 18th. BMO Capital Markets increased their price objective on shares of Abbott Laboratories from $87.00 to $94.00 and gave the company an “outperform” rating in a research note on Thursday, July 18th. ValuEngine cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, Raymond James lowered their price objective on shares of Abbott Laboratories from $93.00 to $90.00 and set an “outperform” rating on the stock in a research note on Monday. One research analyst has rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $86.54.

In other news, insider Randel William Woodgrift sold 65,000 shares of the stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $88.01, for a total transaction of $5,720,650.00. Following the transaction, the insider now directly owns 117,562 shares in the company, valued at approximately $10,346,631.62. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Joseph J. Manning sold 47,226 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $85.14, for a total transaction of $4,020,821.64. Following the transaction, the senior vice president now owns 97,755 shares in the company, valued at $8,322,860.70. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 181,497 shares of company stock worth $15,701,810. 0.70% of the stock is owned by insiders.

NYSE:ABT traded up $0.09 on Wednesday, reaching $82.08. The stock had a trading volume of 7,830,627 shares, compared to its average volume of 4,132,401. The company has a market cap of $140.74 billion, a price-to-earnings ratio of 28.50, a P/E/G ratio of 2.24 and a beta of 1.13. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.68 and a quick ratio of 1.20. The firm’s fifty day moving average is $82.92 and its two-hundred day moving average is $81.71. Abbott Laboratories has a 12-month low of $65.44 and a 12-month high of $88.76.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, October 16th. The healthcare product maker reported $0.84 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.84. The company had revenue of $8.08 billion for the quarter, compared to analyst estimates of $8.10 billion. Abbott Laboratories had a net margin of 9.36% and a return on equity of 17.26%. The firm’s quarterly revenue was up 5.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.75 EPS. As a group, research analysts forecast that Abbott Laboratories will post 3.24 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Tuesday, October 15th will be issued a $0.32 dividend. The ex-dividend date is Friday, October 11th. This represents a $1.28 dividend on an annualized basis and a yield of 1.56%. Abbott Laboratories’s dividend payout ratio (DPR) is 44.44%.

About Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

Featured Story: How much can an individual set aside as a catch-up contribution?

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit